← Back to screener

CRISPR Therapeutics AG CRSP

Rank #2032 · Nasdaq · $5.0B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
35.8
P/E
-32.3
P/B
2.64
ROE
-8.2%
Op. Margin
-60.0%
Debt Ratio
17%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -32.3x, P/B 2.64x. Ranks in the top 60% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -8.2%. Ranks in the top 82% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 17%. Ranks in the top 12% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 30885.5% year over year. Ranks in the top 0% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2016$0.0B$-0.0B$-0.0B$-0.0B-2683.0-426
2017$0.0B$-0.0B$-0.0B$0.2B-10416.648
2018$0.0B$-0.1B$-0.0B$0.2B-1319.344
2019$0.0B$-0.1B$-0.1B$0.2B-157.742
2020$0.0B$-0.2B$-0.2B$0.2B-5087.868
2021$0.3B$0.0B$0.1B$0.4B16.142
2022$0.0B$-0.4B$-0.3B$0.9B-49295.538
2023$0.9B$0.4B$0.4B$1.7B40.822
2024$0.0B$-0.7B$-0.7B$2.4B-56190.414
2025$0.4B$-0.2B$-0.2B$1.9B-60.017

← See the full screener